Who is eligible for clinical trial NCT07662213?

Participants must meet the protocol's inclusion criteria for Type 2 Diabetes Mellitus. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT07662213 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-13

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus (NCT07662213)

A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (8 items).

Location: Research Site — Birmingham, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening
T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s)
HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol)
Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure (NYHA II-III); or ≥2 CV risk factors
Body mass index (BMI) of ≥ 23 kg/m2 at screening
Stable body weight (self-reported or documented) for 90 days prior to screening

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Type 1 Diabetes Mellitus (T1DM), secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
Clinically significant condition affecting the upper Gastrointestinal (GI) tract or chronic use of any medication that affects gastric motility or gastric emptying
History of acute or chronic pancreatitis
Severe congestive heart failure (NYHA IV)
History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (201 Sites)

Showing the first 25 of 201 sites.

Research Site — Birmingham, Alabama
Research Site — Mesa, Arizona
Research Site — Phoenix, Arizona
Research Site — Tempe, Arizona
Research Site — Covina, California
Research Site — Encinitas, California
Research Site — Garden Grove, California
Research Site — Loma Linda, California
Research Site — Long Beach, California
Research Site — Pomona, California
Research Site — Sacramento, California
Research Site — Bridgeport, Connecticut
Research Site — Crystal River, Florida
Research Site — Hollywood, Florida
Research Site — Jacksonville, Florida
Research Site — Leesburg, Florida
Research Site — Orlando, Florida
Research Site — Lilburn, Georgia
Research Site — Idaho Falls, Idaho
Research Site — Melrose Park, Illinois
Research Site — Evansville, Indiana
Research Site — Ames, Iowa
Research Site — Wichita, Kansas
Research Site — Bowling Green, Kentucky
Research Site — Rockville, Maryland

📞 Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Type 2 Diabetes Mellitus

Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study — Aurora, Colorado
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes — Tucson, Arizona
Preventing Type 2 Diabetes in Black Emergent Adult — Chapel Hill, North Carolina
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System — Los Angeles, California
A Study of Glycemic Control in Left Ventricular Assist — Rochester, Minnesota
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus — Mesa, Arizona

Explore by condition: All Type 2 Diabetes Mellitus clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗